

CITATION REPORT

List of articles citing

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma

DOI: 10.1111/bcp.13175

British Journal of Clinical Pharmacology, 2017, 83, 846-854.

Source: <https://exaly.com/paper-pdf/67782443/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
63	Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. <i>AAPS Journal</i> , 2016 , 18, 1192-1202	3.7	56
62	Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 970-976	6.1	18
61	Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2017 , 37, 303-309	3.2	34
60	Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. <i>Anti-Cancer Drugs</i> , 2017 , 28, 911-914	2.4	19
59	Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. <i>Hematological Oncology</i> , 2017 , 35, 679-684	1.3	24
58	Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. <i>Drug Metabolism and Disposition</i> , 2017 , 45, 294-305	4	37
57	Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 846-854	3.8	50
56	Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia?. <i>Clinical Journal of Oncology Nursing</i> , 2017 , 21, 604-610	1.1	2
55	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). <i>Clinical Microbiology and Infection</i> , 2018 , 24 Suppl 2, S53-S70	9.5	93
54	Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1185-1198	6.2	4
53	Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 413-421	2.8	14
52	Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. <i>Experimental Animals</i> , 2018 , 67, 71-82	1.8	14
51	Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 435-440	2.3	7
50	Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. <i>Xenobiotica</i> , 2018 , 48, 904-910	2	18
49	Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story. <i>Journal of Pharmaceutical Sciences</i> , 2018 , 107, 495-502	3.9	36
48	Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018 , 93, 401-407	7.1	229
47	Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 871-879	1.9	11

46	Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. <i>Advances in Therapy</i> , 2018 , 35, 2015-2023	4.1	9
45	Antifungal Drugs. <i>Side Effects of Drugs Annual</i> , 2018 , 40, 327-335	0.2	
44	Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report. <i>Frontiers of Medicine</i> , 2018 , 12, 593-599	12	5
43	Small Molecules in Hematology. <i>Recent Results in Cancer Research</i> , 2018 ,	1.5	4
42	Venetoclax: Targeting BCL2 in Hematological Cancers. <i>Recent Results in Cancer Research</i> , 2018 , 212, 215-242		13
41	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	39
40	Inhibition of proliferation and migration of melanoma cells by ketoconazole and immunomodulatory proteins. <i>Oncology Letters</i> , 2019 , 18, 891-897	2.6	4
39	Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis. <i>Clinical and Translational Science</i> , 2019 , 12, 625-632	4.9	5
38	Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. <i>Hematological Oncology</i> , 2019 , 37, 464-473	1.3	12
37	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Targeted Oncology</i> , 2019 , 14, 493-504	5	4
36	Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1621-1634	6.2	6
35	Identifying and targeting cancer-specific metabolism with network-based drug target prediction. <i>EBioMedicine</i> , 2019 , 43, 98-106	8.8	27
34	Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 9	7.8	21
33	Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1091-1100	6.2	8
32	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1277-1284	2.2	320
31	A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 503-523	6.2	5
30	Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 56-65	1.9	2
29	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 7-23	6.2	

28	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , 2020 , 99, 1989-2007	3	11
27	Simultaneous determination the concentration change of ketoconazole and dexamethasone acetate: application to drug-drug interaction in human keratinocyte. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 188, 113396	3.5	0
26	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , 2020 , 21, 551-560	21.7	34
25	Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. <i>Clinical and Translational Science</i> , 2020 , 13, 555-562	4.9	3
24	Cell Death Pathways in Lymphoid Malignancies. <i>Current Oncology Reports</i> , 2020 , 22, 10	6.3	9
23	Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 465-474	3.5	3
22	Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?. <i>Expert Review of Hematology</i> , 2021 , 14, 199-210	2.8	3
21	BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 66	5.4	4
20	A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
19	Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1152, 122176	3.2	6
18	Functional characterization of a unique cytochrome P450 in. <i>Oncotarget</i> , 2017 , 8, 115079-115088	3.3	5
17	Imidazole Antifungals: A Review of Their Action Mechanisms on Cancerous Cells. <i>International Journal of Secondary Metabolite</i> , 139-159	0.5	1
16	Application and research progress of BCL2 inhibitors in elderly patients with hematologic malignancies. <i>Aging Pathobiology and Therapeutics</i> , 2020 , 2, 180-186	2.4	
15	Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Patients with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy.. <i>Hematological Oncology</i> , 2022 ,	1.3	0
14	Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. <i>Lancet Haematology</i> , 2021 ,	14.6	6
13	Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	1
12	Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	0
11	Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations.. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	3

10	Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.. <i>Leukemia Research</i> , 2022 , 117, 106844	2.7	○
9	Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase IIb Study and Phase III CLL14 Trial. <i>Advances in Therapy</i> ,	4.1	
8	Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 1-8	1.9	
7	Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax. <i>Pharmaceutical Research</i> ,	4.5	○
6	Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.		
5	Quantitation of Venetoclax in Human Plasma by High-Performance Liquid Chromatography with Ultraviolet Detection.		○
4	Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: a proof-of-concept case study..		1
3	Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients. 2023 , 227, 115279		○
2	Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report. 2023 , 21, 102-107		○
1	Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.		○